Icon

OZEMPIC (nda209637)- (2MG/1.5ML (1.34MG/ML),2MG/3ML (0.68MG/ML),4MG/3ML (1.34MG/ML),8MG/3ML (2.68MG/ML))

SEMAGLUTIDE NOVO
2MG/1.5ML (1.34MG/ML),2MG/3ML (0.68MG/ML),4MG/3ML (1.34MG/ML),8MG/3ML (2.68MG/ML)
Yes No
2033-Jun-21 2022-Dec-05
None None
None No
OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as:  an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.  to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
0 0 0
Total Other Developers 33
Drugs with Suitability No
2MG/1.5ML (1.34MG/ML) ** ** Up - -
2MG/3ML (0.68MG/ML) ** ** - - -
4MG/3ML (1.34MG/ML) ** ** Up - -
8MG/3ML (2.68MG/ML) ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.